Regeneron Pharmaceuticals (REGN) Net Cash Flow Growth (1y) (2010 - 2026)
Regeneron Pharmaceuticals (REGN) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 53.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -125.22% |
| Dec 31, 2025 | 27.83% |
| Sep 30, 2025 | 501.33% |
| Jun 30, 2025 | -58.20% |
| Mar 31, 2025 | 573.25% |
| Dec 31, 2024 | -17.23% |
| Sep 30, 2024 | -60.70% |
| Jun 30, 2024 | 65.57% |
| Mar 31, 2024 | -115.75% |
| Dec 31, 2023 | 249.82% |
| Sep 30, 2023 | 119.02% |
| Jun 30, 2023 | -4,105.47% |
| Mar 31, 2023 | 75.54% |
| Dec 31, 2022 | 29.52% |
| Sep 30, 2022 | -92.93% |
| Jun 30, 2022 | -92.21% |
| Mar 31, 2022 | 160.92% |
| Dec 31, 2021 | -188.09% |
| Sep 30, 2021 | 425.33% |
| Jun 30, 2021 | 393.66% |